Decoding the Connection: Cervicovaginal Microbiome, HPV, and Cervical Cancer
-
Naeimeh Tayebi
,
Samira Bahrami
,
Marzieh Mehrabinia
,
Tahmine Mohammad Hosseini
,
Bafrin Xayat6
,
Sogol Nastarvand
,
Maryam Banar
Abstract
In low- and middle-income countries (LMICs), where access to screenings and preventative care is restricted, cervical cancer continues to pose a serious threat to world health. In these areas, it is the third most prevalent cancer among women, and increased incidence and mortality are a result of resource inequities. The human papillomavirus (HPV), a sexually transmitted infection, is the main cause of cervical cancer. Nonetheless, studies reveal a complex interplay among environmental, genetic, and epigenetic factors, with mounting evidence supporting the role of the cervicovaginal microbiome. This microbial community controls vaginal health and modulates HPV risks, with some bacterial species, such as those linked to bacterial vaginosis (e.g., Lactobacillus iners), potentially promoting HPV persistence and cervical dysplasia. On the other hand, beneficial species, including Lactobacillus crispatus and Lactobacillus gasseri, contribute to an acidic environment that counters inflammation and may limit HPV progression. Although progress has been made in understanding these dynamics, much remains unknown about the factors influencing microbiome variability and how to manipulate it to prevent disease. Meanwhile, established preventive measures, such as HPV vaccination, routine screenings, and early treatment of precancerous lesions, have proven effective. However, logistical and financial challenges in LMICs hinder broader implementation. To reduce the global burden, efforts must focus on affordable vaccines, integrated screening services, and increasing public awareness. Further microbiome research offers hope for innovative prevention and treatments. Addressing systemic barriers and advancing knowledge could signify meaningful steps toward eradicating cervical cancer as a public health threat worldwide.
[1] Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical Cancer Screening: A Review. JAMA. 2023;330(6):547-58. https://doi.org/10.1001/jama.2023.13174
[2] Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320-5.
[3] Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007;335(7623):765-8. https://doi.org/10.1136/bmj.39337.615197.80
[4] Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M. Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells. Front Oncol. 2024;13:1277772. https://doi.org/10.3389/fonc.2023.1277772
[5] Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675-86. https://doi.org/10.1093/annonc/mdr015
[6] Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020;32(6):720. https://doi.org/10.21147/j.issn.1000-9604.2020.06.05
[7] World Health Organization. Cervical cancer Mexico 2021 country profile. 2021.
[8] Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre‐cancer: Results from the EPIC cohort. Int J Cancer. 2014;135(2):453-66. https://doi.org/10.1002/ijc.28666
[9] Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, et al. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infect Dis. 2020;20(1):1-12. https://doi.org/10.1186/s12879-020-05324-9
[10] Almeida AM, Queiroz JA, Sousa F, Sousa Â. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discov Today. 2019;24(10):2044-57. https://doi.org/10.1016/j.drudis.2019.07.011
[11] Kashyap N, Krishnan N, Kaur S, Ghai S. Risk factors of cervical cancer: a case-control study. Asia Pac J Oncol Nurs. 2019;6(3):308-14. https://doi.org/10.4103/apjon.apjon_73_18
[12] Curty G, de Carvalho PS, Soares MA. The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. Int J Mol Sci. 2019;21(1):222. https://doi.org/10.3390/ijms21010222
[13] Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020;202(2):323-7. https://doi.org/10.1007/s00203-019-01747-4
[14] Bzhalava D, Eklund C, Dillner J. International standardization and classification of human papillomavirus types. Virology. 2015;476:341-4. https://doi.org/10.1016/j.virol.2014.12.028
[15] Bernard H-U, Burk RD, Chen Z, Van Doorslaer K, Zur Hausen H, de Villiers E-M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70-9. https://doi.org/10.1016/j.virol.2010.02.002
[16] de Sanjose S, Brotons M, Pavon MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2-13. https://doi.org/10.1016/j.bpobgyn.2017.08.015
[17] Melo IMA, Viana MRP, Pupin B, Bhattacharjee TT, de Azevedo Canevari R. PCR-RFLP and FTIR-based detection of high-risk human papilloma virus for cervical cancer screening and prevention. Biochem Biophys Rep. 2021;26:100993. https://doi.org/10.1016/j.bbrep.2021.100993
[18] Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27. https://doi.org/10.1056/NEJMoa021641
[19] Harari A, Chen Z, Burk RD. Human papillomavirus genomics: past, present and future. In: Human Papillomavirus. Vol. 45. Basel: Karger Publishers; 2014. p. 1-18. https://doi.org/10.1159/000355952
[20] Mirabello L, Clarke MA, Nelson CW, Dean M, Wentzensen N, Yeager M, et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Basel: MDPI; 2018. https://doi.org/10.3390/v10020080
[21] Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2):S5-S10. https://doi.org/10.1016/j.ygyno.2010.01.024
[22] Narisawa‐Saito M, Kiyono T. Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505-11. https://doi.org/10.1111/j.1349-7006.2007.00546.x
[23] Yim E-K, Park J-S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319-24. https://doi.org/10.4143/crt.2005.37.6.319
[24] Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol. 2011;51(2):103-8. https://doi.org/10.1111/j.1479-828X.2010.01269.x
[25] Tomaić V. Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers. 2016;8(10):95. https://doi.org/10.3390/cancers8100095
[26] Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high‐risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009;19(2):97-113. https://doi.org/10.1002/rmv.605
[27] Amon P, Sanderson I. What is the microbiome? Arch Dis Child Educ Pract Ed. 2017;102(5):257-60. https://doi.org/10.1136/archdischild-2016-311643
[28] Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol. 2008;125(3):286-92. https://doi.org/10.1016/j.ijfoodmicro.2008.04.012
[29] Champer M, Wong A, Champer J, Brito I, Messer P, Hou J, Wright J. The role of the vaginal microbiome in gynaecological cancer. BJOG. 2018;125(3):309-15. https://doi.org/10.1111/1471-0528.14631
[30] Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019;44:675-90. https://doi.org/10.1016/j.ebiom.2019.04.028
[31] Klein CG. The Relationship Between the Cervical Microbiome and Cervical Cancer Risk in Sub-Saharan Africa [dissertation]. Lincoln (NE): University of Nebraska-Lincoln; 2020.
[32] Sasivimolrattana T, Chantratita W, Sensorn I, Chaiwongkot A, Oranratanaphan S, Bhattarakosol P, Bhattarakosol P. Cervical Microbiome in Women Infected with HPV16 and High-Risk HPVs. Int J Environ Res Public Health. 2022;19(22):14716. https://doi.org/10.3390/ijerph192214716
[33] Kyrgiou M, Mitra A, Moscicki A-B. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res. 2017;179:168-82. https://doi.org/10.1016/j.trsl.2016.07.004
[34] Frąszczak K, Barczyński B, Kondracka A. Does lactobacillus exert a protective effect on the development of cervical and endometrial cancer in women? Cancers. 2022;14(19):4909. https://doi.org/10.3390/cancers14194909
[35] Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-Barnetche J, Cortina-Ceballos B, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. PLoS One. 2016;11(4):e0153274. https://doi.org/10.1371/journal.pone.0153274
[36] Yang X, Da M, Zhang W, Qi Q, Zhang C, Han S. Role of Lactobacillus in cervical cancer. Cancer Manag Res. 2018;10:1219-29. https://doi.org/10.2147/CMAR.S165228
[37] Zadravec P, Štrukelj B, Berlec A. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species. Appl Environ Microbiol. 2015;81(6):2098-106. https://doi.org/10.1128/AEM.03694-14
[38] Rajoka MSR, Zhao H, Lu Y, Lian Z, Li N, Hussain N, et al. Anticancer potential against cervix cancer (HeLa) cell line of probiotic Lactobacillus casei and Lactobacillus paracasei strains isolated from human breast milk. Food Funct. 2018;9(5):2705-15. https://doi.org/10.1039/C8FO00547H
[39] Jimenez NR, Maarsingh JD, Łaniewski P, Herbst-Kralovetz MM. Commensal Lactobacilli Metabolically Contribute to Cervical Epithelial Homeostasis in a Species-Specific Manner. mSphere. 2023;8(1):e00452-22. https://doi.org/10.1128/msphere.00452-22
[40] Pawar K, Aranha C. Lactobacilli metabolites restore E-cadherin and suppress MMP9 in cervical cancer cells. Curr Res Toxicol. 2022;3:100088. https://doi.org/10.1016/j.crtox.2022.100088
[41] Rokos T, Holubekova V, Kolkova Z, Hornakova A, Pribulova T, Kozubik E, et al. Is the Physiological Composition of the Vaginal Microbiome Altered in High-Risk HPV Infection of the Uterine Cervix? Viruses. 2022;14(10):2130. https://doi.org/10.3390/v14102130
[42] Chorna N, Romaguera J, Godoy-Vitorino F. Cervicovaginal microbiome and urine metabolome paired analysis reveals niche partitioning of the microbiota in patients with human papilloma virus infections. Metabolites. 2020;10(1):36. https://doi.org/10.3390/metabo10010036
[43] Li Y, Yu T, Yan H, Li D, Yu T, Yuan T, et al. Vaginal microbiota and HPV infection: novel mechanistic insights and therapeutic strategies. Infect Drug Resist. 2020;13:1213-20. https://doi.org/10.2147/IDR.S210615
[44] Mitra A, MacIntyre D, Lee Y, Smith A, Marchesi JR, Lehne B, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2015;5(1):16865. https://doi.org/10.1038/srep16865
[45] Liu J, Luo M, Zhang Y, Cao G, Wang S. Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition. Ann Transl Med. 2020;8(18):1161. https://doi.org/10.21037/atm-20-5832
[46] Hu S, Ding Q, Zhang W, Kang M, Ma J, Zhao L. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Gut Microbes. 2023;15(1):2236749. https://doi.org/10.1080/19490976.2023.2236749
[47] Zhou Z-W, Long H-Z, Cheng Y, Luo H-Y, Wen D-D, Gao L-C. From microbiome to inflammation: the key drivers of cervical cancer. Front Microbiol. 2021;12:767931. https://doi.org/10.3389/fmicb.2021.767931
[48] Mishra GA, Pimple SA, Shastri SS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol. 2011;32(3):125-32. https://doi.org/10.4103/0971-5851.92808
[49] Maver P, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579-83. https://doi.org/10.1016/j.cmi.2019.09.006
[50] Duggan M, Khalil M, Brasher P, Nation J. Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. Cytopathology. 2006;17(2):73-81. https://doi.org/10.1111/j.1365-2303.2006.00340.x
[51] Singh VB, Gupta N, Nijhawan R, Srinivasan R, Suri V, Rajwanshi A. Liquid-based cytology versus conventional cytology for evaluation of cervical Pap smears: experience from the first 1000 split samples. Indian J Pathol Microbiol. 2015;58(1):17-21. https://doi.org/10.4103/0377-4929.151157
[52] William W, Ware A, Basaza-Ejiri AH, Obungoloch J. A pap-smear analysis tool (PAT) for detection of cervical cancer from pap-smear images. Biomed Eng Online. 2019;18:1-22. https://doi.org/10.1186/s12938-019-0634-5
[53] Ampazis N, Dounias G, Jantzen J. Pap-smear classification using efficient second order neural network training algorithms. In: Vouros GA, Panayiotopoulos T, editors. Methods and Applications of Artificial Intelligence (SETN 2004). Berlin: Springer; 2004. p. 230-9. https://doi.org/10.1007/978-3-540-24674-9_25
[54] Sharma M, Singh SK, Agrawal P, Madaan V. Classification of clinical dataset of cervical cancer using KNN. Indian J Sci Technol. 2016;9(28):1-5. https://doi.org/10.17485/ijst/2016/v9i28/98380
[55] Chankong T, Theera-Umpon N, Auephanwiriyakul S. Automatic cervical cell segmentation and classification in Pap smears. Comput Methods Programs Biomed. 2014;113(2):539-56. https://doi.org/10.1016/j.cmpb.2013.12.012
[56] Kumar R, Srivastava R, Srivastava S. Detection and classification of cancer from microscopic biopsy images using clinically significant and biologically interpretable features. J Med Eng. 2015;2015:457906. https://doi.org/10.1155/2015/457906
[57] Su J, Xu X, He Y, Song J. Automatic detection of cervical cancer cells by a two-level cascade classification system. Anal Cell Pathol. 2016;2016:9539372. https://doi.org/10.1155/2016/9535027
[58] Talukdar J, Nath CK, Talukdar P. Fuzzy clustering based image segmentation of pap smear images of cervical cancer cell using FCM algorithm. Int J Adv Res Comput Sci. 2013;3(1):460-2.
[59] Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619-31. https://doi.org/10.1097/01.AOG.0000120143.50098.c7
[60] Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-88. https://doi.org/10.1056/NEJMoa071430
[61] Zhao F-H, Lin MJ, Chen F, Hu S-Y, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11(12):1160-71. https://doi.org/10.1016/S1470-2045(10)70256-4
[62] Vedantham H, Silver MI, Kalpana B, Rekha C, Karuna B, Vidyadhari K, et al. Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1373-80. https://doi.org/10.1158/1055-9965.EPI-09-1282
[63] Nooh AM, Mohamed ME-S, El-Alfy Y. Visual inspection of cervix with acetic acid as a screening modality for cervical cancer. J Low Genit Tract Dis. 2015;19(4):340-4. https://doi.org/10.1097/LGT.0000000000000145
[64] Ruan Y, Liu M, Guo J, Zhao J, Niu S, Li F. Evaluation of the accuracy of colposcopy in detecting high-grade squamous intraepithelial lesion and cervical cancer. Arch Gynecol Obstet. 2020;302:1529-38. https://doi.org/10.1007/s00404-020-05740-x
[65] Vora C, Gupta S. Targeted therapy in cervical cancer. ESMO Open. 2018;3:e000462. https://doi.org/10.1136/esmoopen-2018-000462
[66] Crafton SM, Salani R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin Ther. 2016;38(3):449-58. https://doi.org/10.1016/j.clinthera.2016.02.007
[67] Wei X-w, Zhang Z-r, Wei Y-Q. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment. Expert Opin Investig Drugs. 2013;22(9):1181-92. https://doi.org/10.1517/13543784.2013.812071
[68] Fujimoto J. Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res. 2009;29(7):2665-9.
[69] Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G, Lorusso D. Role of immune checkpoint inhibitors in cervical cancer: from preclinical to clinical data. Cancers. 2021;13(9):2089. https://doi.org/10.3390/cancers13092089
[70] Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther. 2018;5(2):1-4. https://doi.org/10.15761/ICST.1000272
[71] Otter S, Chatterjee J, Stewart A, Michael A. The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer. Clin Oncol. 2019;31(12):834-43. https://doi.org/10.1016/j.clon.2019.07.003
[72] Zam W, Ali L. Immune checkpoint inhibitors in the treatment of cancer. Curr Rev Clin Exp Pharmacol. 2022;17(2):103-13. https://doi.org/10.2174/1574884716666210325095022
[73] Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021;113(10):1329-35. https://doi.org/10.1093/jnci/djab080
[74] Hussein WM, Liu T-Y, Jia Z, McMillan NA, Monteiro MJ, Toth I, Skwarczynski M. Multiantigenic peptide-polymer conjugates as therapeutic vaccines against cervical cancer. Bioorg Med Chem. 2016;24(18):4372-80. https://doi.org/10.1016/j.bmc.2016.07.036
[75] Yadav N, Parveen S, Banerjee M. Potential of nano-phytochemicals in cervical cancer therapy. Clin Chim Acta. 2020;505:60-72. https://doi.org/10.1016/j.cca.2020.01.035
[76] Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, et al. Nano-based approved pharmaceuticals for cancer treatment: Present and future challenges. Biomolecules. 2022;12(6):784. https://doi.org/10.3390/biom12060784
[77] Ordikhani F, Erdem Arslan M, Marcelo R, Sahin I, Grigsby P, Schwarz JK, Azab AK. Drug delivery approaches for the treatment of cervical cancer. Pharmaceutics. 2016;8(3):23. https://doi.org/10.3390/pharmaceutics8030023
[78] Lappalainen K, Pirilä L, Jääskeläinen I, Syrjänen K, Syrjänen S. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anticancer Res. 1996;16(5A):2485-92.
[79] Chapoy-Villanueva H, Martinez-Carlin I, Lopez-Berestein G, Chavez-Reyes A. Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. J BUON. 2015;20(6):1471-9.
[80] Niu X, Peng Z, Duan W, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006;16(2):743-9. https://doi.org/10.1136/ijgc-00009577-200603000-00044
[81] Zeng X, Tao W, Mei L, Huang L, Tan C, Feng S-S. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013;34(25):6058-67. https://doi.org/10.1016/j.biomaterials.2013.04.052
[82] Saini J, Bansal V, Chandra A, Madan J, Jain UK, Chandra R, Jain SM. Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells. Colloids Surf B Biointerfaces. 2014;118:101-10. https://doi.org/10.1016/j.colsurfb.2014.03.036
[83] Hiorth M, Liereng L, Reinertsen R, Tho I. Formulation of bioadhesive hexylaminolevulinate pellets intended for photodynamic therapy in the treatment of cervical cancer. Int J Pharm. 2013;441(1-2):544-54. https://doi.org/10.1016/j.ijpharm.2012.10.046
[84] Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother. 2008;57:517-30. https://doi.org/10.1007/s00262-007-0390-4
[85] Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, et al. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses. Exp Mol Pathol. 2012;92(1):185-90. https://doi.org/10.1016/j.yexmp.2011.10.002
[86] Byagari K, Shanavas A, Rengan A, Kundu G, Srivastava R. Biocompatible amphiphilic pentablock copolymeric nanoparticles for anti-cancer drug delivery. J Biomed Nanotechnol. 2014;10(1):109-19. https://doi.org/10.1166/jbn.2014.1791
[87] Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, et al. Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv. 2011;8(3):307-19. https://doi.org/10.2174/156720111795256129
[88] Chen X, Zhu K, Xu Y, Tang X, Cai X, Zhang X, Cheng H. RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin Exp Dermatol. 2010;35(5):509-15. https://doi.org/10.1111/j.1365-2230.2009.03624.x
[89] Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G. Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. Int J Pharm. 2015;483(1-2):268-77. https://doi.org/10.1016/j.ijpharm.2015.02.041
[90] Gupta S, Gupta MK. Possible role of nanocarriers in drug delivery against cervical cancer. Nano Rev Exp. 2017;8(1):1335567. https://doi.org/10.1080/20022727.2017.1335567
[91] Jiang M, Rubbi CP, Milner J. Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides. 2004;14(4):239-48. https://doi.org/10.1089/oli.2004.14.239
[92] Li J-g, Li L, Zhang S-w, Wei X. HPV16E7-specific siRNA inhibits cell proliferation in CaSki cells. Cell Biochem Biophys. 2015;71:529-34. https://doi.org/10.1007/s12013-014-0223-y
[93] Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother. 2005;54:1180-90. https://doi.org/10.1007/s00262-005-0685-2
[94] Gu Q, Xing JZ, Huang M, Zhang X, Chen J. Nanoformulation of paclitaxel to enhance cancer therapy. J Biomater Appl. 2013;28(2):298-307. https://doi.org/10.1177/0885328212446822
[95] Cui Z, Han S-J, Huang L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res. 2004;21:1018-25. https://doi.org/10.1023/B:PHAM.0000029292.66792.4f
[96] Wang Z, Wu Y, Zeng X, Ma Y, Liu J, Tang X, et al. Antitumor efficiency of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer. J Biomed Nanotechnol. 2014;10(8):1509-19. https://doi.org/10.1166/jbn.2014.1844
[97] Casañas Pimentel R, San Martín Martínez E, Monroy García A, Gómez-García C, Alvarado Palacios QG. Silver nanoparticles nanocarriers, synthesis and toxic effect on cervical cancer cell lines. BioNanoScience. 2013;3:198-207. https://doi.org/10.1007/s12668-013-0085-6
[2] Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320-5.
[3] Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007;335(7623):765-8. https://doi.org/10.1136/bmj.39337.615197.80
[4] Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M. Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells. Front Oncol. 2024;13:1277772. https://doi.org/10.3389/fonc.2023.1277772
[5] Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675-86. https://doi.org/10.1093/annonc/mdr015
[6] Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020;32(6):720. https://doi.org/10.21147/j.issn.1000-9604.2020.06.05
[7] World Health Organization. Cervical cancer Mexico 2021 country profile. 2021.
[8] Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre‐cancer: Results from the EPIC cohort. Int J Cancer. 2014;135(2):453-66. https://doi.org/10.1002/ijc.28666
[9] Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, et al. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infect Dis. 2020;20(1):1-12. https://doi.org/10.1186/s12879-020-05324-9
[10] Almeida AM, Queiroz JA, Sousa F, Sousa Â. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discov Today. 2019;24(10):2044-57. https://doi.org/10.1016/j.drudis.2019.07.011
[11] Kashyap N, Krishnan N, Kaur S, Ghai S. Risk factors of cervical cancer: a case-control study. Asia Pac J Oncol Nurs. 2019;6(3):308-14. https://doi.org/10.4103/apjon.apjon_73_18
[12] Curty G, de Carvalho PS, Soares MA. The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. Int J Mol Sci. 2019;21(1):222. https://doi.org/10.3390/ijms21010222
[13] Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020;202(2):323-7. https://doi.org/10.1007/s00203-019-01747-4
[14] Bzhalava D, Eklund C, Dillner J. International standardization and classification of human papillomavirus types. Virology. 2015;476:341-4. https://doi.org/10.1016/j.virol.2014.12.028
[15] Bernard H-U, Burk RD, Chen Z, Van Doorslaer K, Zur Hausen H, de Villiers E-M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70-9. https://doi.org/10.1016/j.virol.2010.02.002
[16] de Sanjose S, Brotons M, Pavon MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2-13. https://doi.org/10.1016/j.bpobgyn.2017.08.015
[17] Melo IMA, Viana MRP, Pupin B, Bhattacharjee TT, de Azevedo Canevari R. PCR-RFLP and FTIR-based detection of high-risk human papilloma virus for cervical cancer screening and prevention. Biochem Biophys Rep. 2021;26:100993. https://doi.org/10.1016/j.bbrep.2021.100993
[18] Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27. https://doi.org/10.1056/NEJMoa021641
[19] Harari A, Chen Z, Burk RD. Human papillomavirus genomics: past, present and future. In: Human Papillomavirus. Vol. 45. Basel: Karger Publishers; 2014. p. 1-18. https://doi.org/10.1159/000355952
[20] Mirabello L, Clarke MA, Nelson CW, Dean M, Wentzensen N, Yeager M, et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Basel: MDPI; 2018. https://doi.org/10.3390/v10020080
[21] Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2):S5-S10. https://doi.org/10.1016/j.ygyno.2010.01.024
[22] Narisawa‐Saito M, Kiyono T. Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505-11. https://doi.org/10.1111/j.1349-7006.2007.00546.x
[23] Yim E-K, Park J-S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319-24. https://doi.org/10.4143/crt.2005.37.6.319
[24] Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol. 2011;51(2):103-8. https://doi.org/10.1111/j.1479-828X.2010.01269.x
[25] Tomaić V. Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers. 2016;8(10):95. https://doi.org/10.3390/cancers8100095
[26] Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high‐risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009;19(2):97-113. https://doi.org/10.1002/rmv.605
[27] Amon P, Sanderson I. What is the microbiome? Arch Dis Child Educ Pract Ed. 2017;102(5):257-60. https://doi.org/10.1136/archdischild-2016-311643
[28] Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol. 2008;125(3):286-92. https://doi.org/10.1016/j.ijfoodmicro.2008.04.012
[29] Champer M, Wong A, Champer J, Brito I, Messer P, Hou J, Wright J. The role of the vaginal microbiome in gynaecological cancer. BJOG. 2018;125(3):309-15. https://doi.org/10.1111/1471-0528.14631
[30] Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019;44:675-90. https://doi.org/10.1016/j.ebiom.2019.04.028
[31] Klein CG. The Relationship Between the Cervical Microbiome and Cervical Cancer Risk in Sub-Saharan Africa [dissertation]. Lincoln (NE): University of Nebraska-Lincoln; 2020.
[32] Sasivimolrattana T, Chantratita W, Sensorn I, Chaiwongkot A, Oranratanaphan S, Bhattarakosol P, Bhattarakosol P. Cervical Microbiome in Women Infected with HPV16 and High-Risk HPVs. Int J Environ Res Public Health. 2022;19(22):14716. https://doi.org/10.3390/ijerph192214716
[33] Kyrgiou M, Mitra A, Moscicki A-B. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res. 2017;179:168-82. https://doi.org/10.1016/j.trsl.2016.07.004
[34] Frąszczak K, Barczyński B, Kondracka A. Does lactobacillus exert a protective effect on the development of cervical and endometrial cancer in women? Cancers. 2022;14(19):4909. https://doi.org/10.3390/cancers14194909
[35] Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-Barnetche J, Cortina-Ceballos B, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. PLoS One. 2016;11(4):e0153274. https://doi.org/10.1371/journal.pone.0153274
[36] Yang X, Da M, Zhang W, Qi Q, Zhang C, Han S. Role of Lactobacillus in cervical cancer. Cancer Manag Res. 2018;10:1219-29. https://doi.org/10.2147/CMAR.S165228
[37] Zadravec P, Štrukelj B, Berlec A. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species. Appl Environ Microbiol. 2015;81(6):2098-106. https://doi.org/10.1128/AEM.03694-14
[38] Rajoka MSR, Zhao H, Lu Y, Lian Z, Li N, Hussain N, et al. Anticancer potential against cervix cancer (HeLa) cell line of probiotic Lactobacillus casei and Lactobacillus paracasei strains isolated from human breast milk. Food Funct. 2018;9(5):2705-15. https://doi.org/10.1039/C8FO00547H
[39] Jimenez NR, Maarsingh JD, Łaniewski P, Herbst-Kralovetz MM. Commensal Lactobacilli Metabolically Contribute to Cervical Epithelial Homeostasis in a Species-Specific Manner. mSphere. 2023;8(1):e00452-22. https://doi.org/10.1128/msphere.00452-22
[40] Pawar K, Aranha C. Lactobacilli metabolites restore E-cadherin and suppress MMP9 in cervical cancer cells. Curr Res Toxicol. 2022;3:100088. https://doi.org/10.1016/j.crtox.2022.100088
[41] Rokos T, Holubekova V, Kolkova Z, Hornakova A, Pribulova T, Kozubik E, et al. Is the Physiological Composition of the Vaginal Microbiome Altered in High-Risk HPV Infection of the Uterine Cervix? Viruses. 2022;14(10):2130. https://doi.org/10.3390/v14102130
[42] Chorna N, Romaguera J, Godoy-Vitorino F. Cervicovaginal microbiome and urine metabolome paired analysis reveals niche partitioning of the microbiota in patients with human papilloma virus infections. Metabolites. 2020;10(1):36. https://doi.org/10.3390/metabo10010036
[43] Li Y, Yu T, Yan H, Li D, Yu T, Yuan T, et al. Vaginal microbiota and HPV infection: novel mechanistic insights and therapeutic strategies. Infect Drug Resist. 2020;13:1213-20. https://doi.org/10.2147/IDR.S210615
[44] Mitra A, MacIntyre D, Lee Y, Smith A, Marchesi JR, Lehne B, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2015;5(1):16865. https://doi.org/10.1038/srep16865
[45] Liu J, Luo M, Zhang Y, Cao G, Wang S. Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition. Ann Transl Med. 2020;8(18):1161. https://doi.org/10.21037/atm-20-5832
[46] Hu S, Ding Q, Zhang W, Kang M, Ma J, Zhao L. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Gut Microbes. 2023;15(1):2236749. https://doi.org/10.1080/19490976.2023.2236749
[47] Zhou Z-W, Long H-Z, Cheng Y, Luo H-Y, Wen D-D, Gao L-C. From microbiome to inflammation: the key drivers of cervical cancer. Front Microbiol. 2021;12:767931. https://doi.org/10.3389/fmicb.2021.767931
[48] Mishra GA, Pimple SA, Shastri SS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol. 2011;32(3):125-32. https://doi.org/10.4103/0971-5851.92808
[49] Maver P, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579-83. https://doi.org/10.1016/j.cmi.2019.09.006
[50] Duggan M, Khalil M, Brasher P, Nation J. Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. Cytopathology. 2006;17(2):73-81. https://doi.org/10.1111/j.1365-2303.2006.00340.x
[51] Singh VB, Gupta N, Nijhawan R, Srinivasan R, Suri V, Rajwanshi A. Liquid-based cytology versus conventional cytology for evaluation of cervical Pap smears: experience from the first 1000 split samples. Indian J Pathol Microbiol. 2015;58(1):17-21. https://doi.org/10.4103/0377-4929.151157
[52] William W, Ware A, Basaza-Ejiri AH, Obungoloch J. A pap-smear analysis tool (PAT) for detection of cervical cancer from pap-smear images. Biomed Eng Online. 2019;18:1-22. https://doi.org/10.1186/s12938-019-0634-5
[53] Ampazis N, Dounias G, Jantzen J. Pap-smear classification using efficient second order neural network training algorithms. In: Vouros GA, Panayiotopoulos T, editors. Methods and Applications of Artificial Intelligence (SETN 2004). Berlin: Springer; 2004. p. 230-9. https://doi.org/10.1007/978-3-540-24674-9_25
[54] Sharma M, Singh SK, Agrawal P, Madaan V. Classification of clinical dataset of cervical cancer using KNN. Indian J Sci Technol. 2016;9(28):1-5. https://doi.org/10.17485/ijst/2016/v9i28/98380
[55] Chankong T, Theera-Umpon N, Auephanwiriyakul S. Automatic cervical cell segmentation and classification in Pap smears. Comput Methods Programs Biomed. 2014;113(2):539-56. https://doi.org/10.1016/j.cmpb.2013.12.012
[56] Kumar R, Srivastava R, Srivastava S. Detection and classification of cancer from microscopic biopsy images using clinically significant and biologically interpretable features. J Med Eng. 2015;2015:457906. https://doi.org/10.1155/2015/457906
[57] Su J, Xu X, He Y, Song J. Automatic detection of cervical cancer cells by a two-level cascade classification system. Anal Cell Pathol. 2016;2016:9539372. https://doi.org/10.1155/2016/9535027
[58] Talukdar J, Nath CK, Talukdar P. Fuzzy clustering based image segmentation of pap smear images of cervical cancer cell using FCM algorithm. Int J Adv Res Comput Sci. 2013;3(1):460-2.
[59] Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619-31. https://doi.org/10.1097/01.AOG.0000120143.50098.c7
[60] Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-88. https://doi.org/10.1056/NEJMoa071430
[61] Zhao F-H, Lin MJ, Chen F, Hu S-Y, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11(12):1160-71. https://doi.org/10.1016/S1470-2045(10)70256-4
[62] Vedantham H, Silver MI, Kalpana B, Rekha C, Karuna B, Vidyadhari K, et al. Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1373-80. https://doi.org/10.1158/1055-9965.EPI-09-1282
[63] Nooh AM, Mohamed ME-S, El-Alfy Y. Visual inspection of cervix with acetic acid as a screening modality for cervical cancer. J Low Genit Tract Dis. 2015;19(4):340-4. https://doi.org/10.1097/LGT.0000000000000145
[64] Ruan Y, Liu M, Guo J, Zhao J, Niu S, Li F. Evaluation of the accuracy of colposcopy in detecting high-grade squamous intraepithelial lesion and cervical cancer. Arch Gynecol Obstet. 2020;302:1529-38. https://doi.org/10.1007/s00404-020-05740-x
[65] Vora C, Gupta S. Targeted therapy in cervical cancer. ESMO Open. 2018;3:e000462. https://doi.org/10.1136/esmoopen-2018-000462
[66] Crafton SM, Salani R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin Ther. 2016;38(3):449-58. https://doi.org/10.1016/j.clinthera.2016.02.007
[67] Wei X-w, Zhang Z-r, Wei Y-Q. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment. Expert Opin Investig Drugs. 2013;22(9):1181-92. https://doi.org/10.1517/13543784.2013.812071
[68] Fujimoto J. Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res. 2009;29(7):2665-9.
[69] Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G, Lorusso D. Role of immune checkpoint inhibitors in cervical cancer: from preclinical to clinical data. Cancers. 2021;13(9):2089. https://doi.org/10.3390/cancers13092089
[70] Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther. 2018;5(2):1-4. https://doi.org/10.15761/ICST.1000272
[71] Otter S, Chatterjee J, Stewart A, Michael A. The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer. Clin Oncol. 2019;31(12):834-43. https://doi.org/10.1016/j.clon.2019.07.003
[72] Zam W, Ali L. Immune checkpoint inhibitors in the treatment of cancer. Curr Rev Clin Exp Pharmacol. 2022;17(2):103-13. https://doi.org/10.2174/1574884716666210325095022
[73] Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021;113(10):1329-35. https://doi.org/10.1093/jnci/djab080
[74] Hussein WM, Liu T-Y, Jia Z, McMillan NA, Monteiro MJ, Toth I, Skwarczynski M. Multiantigenic peptide-polymer conjugates as therapeutic vaccines against cervical cancer. Bioorg Med Chem. 2016;24(18):4372-80. https://doi.org/10.1016/j.bmc.2016.07.036
[75] Yadav N, Parveen S, Banerjee M. Potential of nano-phytochemicals in cervical cancer therapy. Clin Chim Acta. 2020;505:60-72. https://doi.org/10.1016/j.cca.2020.01.035
[76] Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, et al. Nano-based approved pharmaceuticals for cancer treatment: Present and future challenges. Biomolecules. 2022;12(6):784. https://doi.org/10.3390/biom12060784
[77] Ordikhani F, Erdem Arslan M, Marcelo R, Sahin I, Grigsby P, Schwarz JK, Azab AK. Drug delivery approaches for the treatment of cervical cancer. Pharmaceutics. 2016;8(3):23. https://doi.org/10.3390/pharmaceutics8030023
[78] Lappalainen K, Pirilä L, Jääskeläinen I, Syrjänen K, Syrjänen S. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anticancer Res. 1996;16(5A):2485-92.
[79] Chapoy-Villanueva H, Martinez-Carlin I, Lopez-Berestein G, Chavez-Reyes A. Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. J BUON. 2015;20(6):1471-9.
[80] Niu X, Peng Z, Duan W, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006;16(2):743-9. https://doi.org/10.1136/ijgc-00009577-200603000-00044
[81] Zeng X, Tao W, Mei L, Huang L, Tan C, Feng S-S. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013;34(25):6058-67. https://doi.org/10.1016/j.biomaterials.2013.04.052
[82] Saini J, Bansal V, Chandra A, Madan J, Jain UK, Chandra R, Jain SM. Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells. Colloids Surf B Biointerfaces. 2014;118:101-10. https://doi.org/10.1016/j.colsurfb.2014.03.036
[83] Hiorth M, Liereng L, Reinertsen R, Tho I. Formulation of bioadhesive hexylaminolevulinate pellets intended for photodynamic therapy in the treatment of cervical cancer. Int J Pharm. 2013;441(1-2):544-54. https://doi.org/10.1016/j.ijpharm.2012.10.046
[84] Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother. 2008;57:517-30. https://doi.org/10.1007/s00262-007-0390-4
[85] Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, et al. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses. Exp Mol Pathol. 2012;92(1):185-90. https://doi.org/10.1016/j.yexmp.2011.10.002
[86] Byagari K, Shanavas A, Rengan A, Kundu G, Srivastava R. Biocompatible amphiphilic pentablock copolymeric nanoparticles for anti-cancer drug delivery. J Biomed Nanotechnol. 2014;10(1):109-19. https://doi.org/10.1166/jbn.2014.1791
[87] Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, et al. Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv. 2011;8(3):307-19. https://doi.org/10.2174/156720111795256129
[88] Chen X, Zhu K, Xu Y, Tang X, Cai X, Zhang X, Cheng H. RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin Exp Dermatol. 2010;35(5):509-15. https://doi.org/10.1111/j.1365-2230.2009.03624.x
[89] Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G. Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. Int J Pharm. 2015;483(1-2):268-77. https://doi.org/10.1016/j.ijpharm.2015.02.041
[90] Gupta S, Gupta MK. Possible role of nanocarriers in drug delivery against cervical cancer. Nano Rev Exp. 2017;8(1):1335567. https://doi.org/10.1080/20022727.2017.1335567
[91] Jiang M, Rubbi CP, Milner J. Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides. 2004;14(4):239-48. https://doi.org/10.1089/oli.2004.14.239
[92] Li J-g, Li L, Zhang S-w, Wei X. HPV16E7-specific siRNA inhibits cell proliferation in CaSki cells. Cell Biochem Biophys. 2015;71:529-34. https://doi.org/10.1007/s12013-014-0223-y
[93] Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother. 2005;54:1180-90. https://doi.org/10.1007/s00262-005-0685-2
[94] Gu Q, Xing JZ, Huang M, Zhang X, Chen J. Nanoformulation of paclitaxel to enhance cancer therapy. J Biomater Appl. 2013;28(2):298-307. https://doi.org/10.1177/0885328212446822
[95] Cui Z, Han S-J, Huang L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res. 2004;21:1018-25. https://doi.org/10.1023/B:PHAM.0000029292.66792.4f
[96] Wang Z, Wu Y, Zeng X, Ma Y, Liu J, Tang X, et al. Antitumor efficiency of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer. J Biomed Nanotechnol. 2014;10(8):1509-19. https://doi.org/10.1166/jbn.2014.1844
[97] Casañas Pimentel R, San Martín Martínez E, Monroy García A, Gómez-García C, Alvarado Palacios QG. Silver nanoparticles nanocarriers, synthesis and toxic effect on cervical cancer cell lines. BioNanoScience. 2013;3:198-207. https://doi.org/10.1007/s12668-013-0085-6
| Files | ||
| Issue | Vol 1 No 1 (2026) | |
| Section | Review Article(s) | |
| Keywords | ||
| Cervical cancer Human papillomavirus Cervicovaginal microbiome Cancer prevention Cancer treatments | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Tayebi N, Bahrami S, Mehrabinia M, Hosseini TM, Xayat6B, Nastarvand S, Banar M. Decoding the Connection: Cervicovaginal Microbiome, HPV, and Cervical Cancer. ipj. 2026;1(1):1-13.
